Understanding the circuits that promote an efficient resolution of inflammation is crucial to deciphering the molecular and cellular processes required to promote tissue repair. Macrophages play a central role in the regulation of inflammation, resolution and repair/regeneration. Using a model of skeletal muscle injury and repair, herein we identify Annexin A1 (AnxA1) as the extracellular trigger of macrophage skewing towards a pro-reparative phenotype. Brought into the injured tissue initially by migrated neutrophils, and then over-expressed in infiltrating macrophages, AnxA1 activates FPR2/ALX receptors and the downstream AMPK signalling cascade leading to macrophage skewing, dampening of inflammation and regeneration of muscle fibres. Mice lacking AnxA1 in all cells or in myeloid cells only display a defect in this reparative process. In vitro experiments recapitulated these properties, with AMPK null macrophages lacking AnxA1-mediated polarization. Collectively, these data identify the AnxA1/FPR2/AMPK axis as a novel pathway in skeletal muscle injury regeneration.
Introduction
An efficient inflammatory response is a necessary component of the reaction to injury or infection, but it is equally critical for this inflammatory response to be terminated in a timely and appropriate manner, enabling the restoration of tissue homeostasis (Perretti et al., 2017; Serhan, 2014) . Indeed, chronic inflammation that results from failure of resolution represents a major contributing factor to a multitude of pathologies, from arthritis to sepsis to dementia Tabas and Glass, 2013 ).
An inflammatory reaction consists of the co-ordinated activity of numerous cells and soluble mediators, but a central role is played by macrophages. These cells, whether resident in the tissue or recruited from circulating monocyte populations, are amongst the first responders to pathogen-or damage-associated molecular patterns, initiating endothelial activation and neutrophil recruitment (Davies and Taylor, 2015) . Beyond their roles as sentinels, macrophages are important drivers of the progression of an inflammatory response, acting to clear pathogens, effete cells and debris by phagocytosis (Mantovani et al., 2013) , serving as antigen presenting cells to recruit the adaptive arm of the immune response (Motwani and Gilroy, 2015) , and ultimately enabling processes of tissue repair and resolution (Lucas et al., 2010; Troidl et al., 2009 ). That one cell type is able to achieve this diverse array of functions is due in large part to their remarkable degree of phenotypic plasticity, with macrophages existing in a wide variety of forms along a spectrum running from a largely proinflammatory state, often indicated as M1, to a primarily non-phlogistic and pro-resolving phenotype, termed M2 (Murray et al., 2014) .
A number of factors promoting this phenotypic transformation have been studied including exposure to anti-inflammatory cytokines such as interleukin (IL)-10 and IL-4, and the phagocytic removal of cell debris, although a complete description of the underlying mechanisms is lacking (Martinez and Gordon, 2014) . We and others have identified a key role for the intracellular signalling pathway governed by AMP-activated protein kinase (AMPK) (Chan et al., 2015; Mounier et al., 2013; Park et al., 2017) . Activation of this pathway is required for efficient conversion of pro-to antiinflammatory-type macrophages, and inhibition of such a response significantly attenuated recovery in a model of inflammatory skeletal muscle injury . Whilst AMPK is undoubtedly important in the phenotypic conversion of macrophages during the course of an inflammatory reaction, the nature of the extracellular trigger(s) for its stimulation remain unclear.
The protein annexin A1 (ANXA1) (Lim and Pervaiz, 2007; Perretti and D'Acquisto, 2009) , is a major driver of inflammatory resolution, promoting neutrophil apoptosis (Solito et al., 2003) , nonphlogistic monocyte recruitment (McArthur et al., 2015) and macrophage efferocytosis (Dalli et al., 2012; Scannell et al., 2007) . Moreover, we and others have recently provided evidence showing ANXA1 to promote an anti-inflammatory macrophage phenotype in in vitro models of rheumatoid arthritis (Rhys et al., 2018) and tumour growth (Moraes et al., 2017) , but how this translates to an in vivo situation is less clear. Against this background, we applied a well-characterised model of skeletal muscle injury (Arnold et al., 2007; Varga et al., 2013; Varga et al., 2016a) to test the hypothesis that ANXA1 and its receptor FPR2/ALX could be the upstream trigger of AMPK activation, and hence be a major driver of the pro-to anti-inflammatory macrophage phenotype shift, promoting inflammatory resolution and the restoration of skeletal muscle tissue homeostasis.
Results

Annexin A1 and Fpr2/3 null mice show impaired recovery from skeletal muscle injury
To investigate the role of ANXA1 and its receptor FPR2/ALX (in humans, or the orthologue Fpr2/3 in mice) in the control of macrophage phenotype we first utilised the murine model of cardiotoxininduced Tibialis Anterior (TA) injury, a model characterised by necrotic tissue damage and extensive macrophage activity (d 'Albis et al., 1988; Mounier et al., 2013) . Analysis of immune cell infiltration in lesioned wild-type mice revealed a typical inflammatory profile, dominated by Ly6G + neutrophils for the initial post-lesioning period, supplanted by F4/80 + macrophages from day 2 onwards (Suppl Fig   1A-B) . Monitoring ANXA1 expression in the tissue revealed that while absent in uninjured tissue, the protein was primarily restricted to immune cells until day 2 post-lesioning, with regenerating muscle fibres displaying weak immunostaining from Day 7 (Suppl Fig 1A-B) , as reported previously (Bizzarro et al., 2012) . Whilst F4/80 + murine macrophages expressed AnxA1 at all time-points examined (Suppl Fig 1B-C) , the proportion of macrophages expressing its primary receptor, Fpr2/3, decreased over time, from approximately 95% at day 2 to 70% at day 7 and just 5% two weeks post-lesioning, even though significant numbers of macrophages were still detected in the tissue ( Suppl Fig 2A-B) .
Importantly, expression of Fpr2/3 on muscle fibers was not apparent at any time-point examined (Suppl Fig 2A) .
Whilst uninjured TA muscle weights were comparable between wild-type, AnxA1 -/-and Fpr2/3 -/-mice ( Fig 1A-B, Suppl Fig 3A) , recovery of muscle mass following administration of cardiotoxin was significantly reduced in AnxA1 -/-and Fpr2/3 -/-mice than in wild-type animals ( Fig 1B) . Histological analysis of muscles 28 days post-injury revealed significantly reduced myofiber cross-sectional area (CSA) and myonuclei per fiber (i.e. the result of differentiation and fusion of muscle stem cells) in AnxA1 -/-and Fpr2/3 -/-animals ( Fig 1C-E) . These outcomes are suggestive of impaired skeletal muscle regeneration, a notion confirmed by marked lipid accumulation in AnxA1 -/-mice ( Fig 1F) . Fig 3B) . Consequently, the resolution index (ratio of anti-to pro-inflammatory macrophages)
of AnxA1 -/-and Fpr2/3 -/-mice was significantly lower than that of wild-type animals, indicative of a prolonged inflammatory response (Fig 1H) . These results indicate that a proportion of pro-inflammatory macrophages fail to convert to an anti-inflammatory phenotype at the time of resolution in the absence of AnxA1 or Fpr2/3.
Macrophages are the major source of AnxA1 in lesion recovery
The more pronounced effects of cardiotoxin in AnxA1 -/-and Fpr2/3 -/-mice indicate the existence of important regulatory functions for this pathway in skeletal muscle injury. However, while Fpr2/3 expression appears restricted to immune cells infiltrating the TA muscle ( Suppl Fig 2) , AnxA1 is expressed markedly by immune cells and to a lower extent by regenerating muscle fibres (Suppl Fig   1) . As such, we deemed it important to define the primary cell source of this mediator in the repair process, a question we addressed using chimeric mice bearing wild-type muscle but AnxA1 -/-bone marrow-derived leukocytes. Therefore, CX3CR1-GFP mice, which harbour GFP-expressing monocytes/macrophages were irradiated and transplanted with wild-type or AnxA1 -/-derived bone marrow cells, prior to injection of cardiotoxin in the TA muscle (Fig 2A) . Analysis of bone marrow populations at the time of euthanasia showed less than 1% of monocytes (CD115 pos cells) expressed GFP, suggesting >99% engraftment efficiency with either wild-type or AnxA1 -/-bone marrow (Fig 2B- C). Weight recovery was similar after wild-type or AnxA1 -/-transplant (Suppl Fig 3C) , but histological analysis of TA muscles 28-days post-CTX injury revealed that animals receiving AnxA1 -/-bone marrow cells displayed a significantly reduced myofiber cross-sectional area than animals receiving wild-type bone marrow cells (Fig 2D-E) . These data indicate that the defective regeneration quantified in AnxA1 -/-muscle is a consequence of an intrinsic defect in myeloid, rather than stromal, cells.
Exogenous ANXA1 can induce human macrophage phenotype conversion in vitro
As our murine analyses indicate a potential role for AnxA1 in the polarization of macrophages from a pro-inflammatory to a pro-resolving/reparative phenotype, we investigated these effects in vitro using human PBMC-derived macrophages. An M1-like macrophage phenotype was induced by 24 h incubation with bacterial lipopolysaccharide (LPS) and γ-interferon (IFNγ), prior to addition of human recombinant ANXA1 (hrANXA1). Following hrANXA1 treatment, analysis of cell surface markers revealed a significant reduction in expression of the M1 marker protein major histocompatibility complex II (MHCII) (Fig 3A) , accompanied by a significant increase in expression of the M2 marker protein CD206 (Fig 3B) . These surface marker changes were mirrored by changes at the transcriptional level, with hrANXA1 treatment inducing a reduction in mRNA expression for the proinflammatory species Tnfa and Nos2 paired with increased message of Il-10 ( Fig. 3C-E) . No significant changes in Tgfb1 expression were quantified (Fig. 3F) . Together, these in vitro data support our in vivo findings, providing evidence that ANXA1 application favours a pro-resolving macrophage phenotype.
The specificity of hrANXA1 action through its human receptor FPR2/ALX was then determined, to complement the in vivo observations made with Fpr2/3 -/-mice lacking the orthologue of the human FPR2/ALX (Dufton et al., 2010) . Intriguingly, we observed significant FPR2/ALX surface expression both in unstimulated human PBMC-derived macrophages and M1-phenotype cells, yet cell surface expression of the receptor was lost on cells stimulated towards an M2 phenotype with IL-4 (Suppl Fig. 4 ). These data are in agreement with the in vivo observation that Fpr2/3 -/-is absent from macrophages that have infiltrated the injured muscle at Day 7 and beyond, that is, when a reparative cell phenotype has been acquired (Suppl Fig 2B-C) . The functional engagement of FPR2/ALX was then confirmed through use of the selective antagonist WRW 4 . The modulatory effects of hrANXA1 on pro-inflammatory PBMC-derived macrophages (i.e. reduced surface MHCII expression and augmented surface CD206 expression) were lost in the presence of WRW 4 ( Fig. 3G-H ).
Together these experiments represent a clear in vitro counterpart to the effects observed in the muscle injury model, showing the key role of ANXA1 acting through FPR2/ALX to drive a shift in macrophage phenotype towards a pro-resolving and reparative polarization.
Exogenous ANXA1 treatment stimulates AMPK activation through FPR2/ALX
The enzyme 5'-adenosine monophosphate-activated protein kinase, AMPK, plays a critical role in macrophage phenotype skewing and is necessary for efficient regeneration after skeletal muscle damage . We queried whether this signalling pathway would underlie the effects of hrANXA1 upon human macrophage phenotype and indeed muscle repair in vivo.
Exposure of human PBMC-derived macrophages to hrANXA1 activated a number of components of the AMPK signalling pathway, promoting phosphorylation of Ca 2+ /calmodulin-dependent protein kinase II, AMPKα1 itself and its downstream effector acetyl-CoA carboxylase (Fig 4A-B) . Interestingly, the phosphorylation of these proteins in macrophages only occurred to an appreciable degree following exposure to hrANXA1 for 30-60 min (Fig 4B-D) , in contrast to early MAP kinase signalling previously reported in human monocytes (McArthur et al., 2015) . That activation of AMPKα1 depended upon binding of hrANXA1 to FPR2/ALX was confirmed through analysis of the effects of the antagonist WRW 4 , which abrogated hrANXA1-evoked AMPKα1 phosphorylation in human macrophages ( Fig 4E) . Analyses of murine bone marrow-derived macrophages from wild-type and Fpr2/3 -/-animals confirmed the pivotal role of this receptor: whilst treatment with hrANXA1 induced phosphorylation of AMPKα1 in wild-type cells, this response was absent in macrophages from Fpr2/3 -/-mice ( Fig 4F) .
AMPK activation is required for macrophage phenotype conversion induced by ANXA1
We investigated the relationship between FPR2/ALX-mediated AMPK activation and the shift in macrophage phenotype induced by hrANXA1 treatment through analyses in primary bone marrowderived macrophages taken from wild-type mice and animals lacking the key catalytic α 1 subunit of AMPK (Jorgensen et al., 2005) . Whilst treatment of wild-type macrophages with hrANXA1 (10nM, 24h) reduced the percentage of macrophages positive for the pro-inflammatory markers iNOS and CCL3, this response was notably absent in cells from AMPKα1 -/-mice ( Fig 5A) . Correspondingly, hrANXA1 treatment augmented the proportion of wild type cells expressing the anti-inflammatory markers TGFβ1 (notably at variance from human macrophages), CD163 and CD206, but this did not occur in cells lacking AMPKα1 ( Fig 5B) . Together, these data indicate activation of AMPKα1 as a key step in the macrophage phenotype shift induced by ANXA1.
To confirm these findings in human cells, we employed an RNA interference approach, transfecting primary PBMC-derived macrophages with three distinct siRNA constructs targeting the AMPKα1 subunit ( 
Adult myogenesis is ANXA1-AMPK signalling dependent in vitro
Together, these data from human and mouse macrophages make a compelling case that macrophage phenotype shifting can be induced through an ANXA1/FPR2/AMPK cascade. To investigate whether this process underlies differences in recovery from cardiotoxin-induced muscle lesions seen between wild-type and AnxA1 -/-and Fpr2/3 -/-mice, we made use of an established model of in vitro muscle repair Varga et al., 2016b) .
We employed an in vitro model of adult myogenesis in which conditioned medium from primary bone marrow-derived macrophages was used to stimulate primary murine myoblasts for 72h, quantifying the proportion of multinucleated myotubes (Fig. 5F ). As such this in vitro setting recapitulates the processes of adult myogenesis (activation, differentiation, migration and fusion of muscle cells) that occur during skeletal muscle regeneration Varga et al., 2016b) . Conditioned medium from ANXA1-treated wild-type macrophages induced an increase in myotube fusion index (Fig 5G-I ). This response was absent when myotubes were treated with conditioned medium from ANXA1-treated AMPKα1 -/-macrophages (Fig 5G-I ).
Discussion
The timely resolution of inflammation is a fundamental requirement for restoring homeostasis following infection or damage, with its failure being a significant contributory factor to numerous chronic inflammatory pathologies. Macrophages are key players in this process, given their ability to transition from generally pro-inflammatory to anti-inflammatory phenotypes (Motwani and Gilroy, 2015) . Substantial effort has gone into deciphering the complex signals underpinning macrophage plasticity, with numerous soluble mediators having been implicated (Martinez and Gordon, 2014) , but the mechanistic link between these factors and changes in phenotype remains poorly understood especially when investigated in specific tissue-restricted settings. In the current study,
we have employed a well-characterised model of muscular injury and recovery to identify the ability of myeloid cell-derived ANXA1 to promote an anti-inflammatory macrophage phenotype, promoting resolution and tissue repair. Moreover, we show the actions of this protein to be mediated through the cell surface receptor FPR2/ALX and consequent activation of the intracellular signalling molecule AMPK, mechanistically linking external and intracellular proresolving signals governing macrophage phenotype.
These data reinforce the status of the ANXA1-FPR2/ALX pair as a major endogenous driver of inflammatory resolution, and add to its known roles in regulating neutrophil apoptosis (Solito et al., 2003) , efferocytosis (Maderna et al., 2005; Scannell et al., 2007) , and the recruitment of monocytes to inflammatory sites (Gobbetti et al., 2014; McArthur et al., 2015) . Notably, despite muscle tissue itself beginning to express ANXA1 during tissue repair, as noted previously (Bizzarro et al., 2012) , experiments with chimeric mice confirmed that the most important source of the protein to enable muscle repair remains the myeloid cells themselves. While the current studies do not permit conclusive determination of whether neutrophils or macrophages are the primary source of endogenous ANXA1 in the injured tissue, neutrophils contain substantial quantities of ANXA1 (Francis et al., 1992 ), which we have previously shown to be a major monocyte chemoattractant (McArthur et al., 2015) suggesting that the protein -produced at an early stage by and released from infiltrating neutrophils (Damazo et al., 2006) -may act to both recruit monocytes and promote a proresolving phenotype in resulting macrophages. Whatever the ultimate cellular source of ANXA1 however, the dependency upon the presence of ANXA1-expressing leukocytes for efficient macrophage phenotypic conversion is another example of how "the beginning programs the end" in resolution (Serhan and Savill, 2005) , emphasising the finely tuned nature of the acute inflammatory response and its ability to encode its own termination.
Besides highlighting the role of ANXA1 as a regulator of inflammatory resolution (Leoni and Nusrat, 2016) , these new data add further weight to the importance of its principal receptor FPR2/ALX in this process, identifying it as a conduit for induction of a pro-resolving macrophage phenotype through AMPK activation. It is notable that macrophage FPR2/ALX expression declined during the course of the response to muscular injury in our study; similarly, FPR2/ALX expression was significantly lower on M2 when compared with M1 phenotype cells in vitro. This change in receptor expression may reflect a strategy whereby once the macrophage is polarised towards a reparative phenotype, the utility of the FPR2/ALX signalling is then limited or unnecessary.
There is considerable redundancy in the mediators known to induce the conversion of macrophage phenotypes, as is perhaps to be expected given the importance of this process to the restoration of homeostasis after infection or damage, including immune complexes, apoptotic cells and a number of cytokines (Amici et al., 2017) . Notably however, a significant proportion of the soluble proresolving mediators so far identified derive from the adaptive arm of the immune response, particularly from T H 2 lymphocytes (Martinez and Gordon, 2014) . Our data however, highlight the ability of signalling components derived from the innate side of the immune system to promote resolution in the absence of significant activation of adaptive mechanisms. Moreover, these results support the concept of how it is crucial to decipher which mediator and signal(s) are operative in specific tissues and organs to control macrophage polarization and the overall process of resolution and repair. whereas immune cells with an anti-inflammatory or pro-resolving profile tend to exhibit greater mitochondrial respiration (Jha et al., 2015; Mounier et al., 2013; Tannahill et al., 2013) . The mechanistic details of how such changes in metabolic phenotype relate to immune function, and indeed whether these differences reflect or drive immunophenotype is unclear (Van den Bossche et al., 2017), but it is notable that AMPK is a significant promoter of mitochondrial respiration and a regulator of glycolysis through the modulation of lactate dehydrogenase activity (Theret et al., 2017) , driven by its ability to respond to energy debt and an increased AMP:ATP ratio (Mounier et al., 2015) . Activation of this pathway would therefore seem ideally placed to induce the metabolic phenotype most closely associated with anti-inflammatory macrophage activation, but this hypothesis requires further investigation.
AMPK is involved in different cellular mechanisms that regulate skeletal muscle homeostasis (Kjobsted et al., 2018) . Our previous findings highlight the importance of crosstalk between AMPK and the mTOR signaling pathway for the control of muscle cell size in the adaptive response of skeletal muscle (Lantier et al., 2014; Lantier et al., 2010; Mounier et al., 2011; Mounier et al., 2009 ).
Moreover, we have recently shown that AMPKα1, activated following phagocytosis, is crucial for macrophage skewing from a pro-to an anti-inflammatory phenotype during resolution , demonstrating that the CAMKKII/AMPKα1 pathway within macrophages is required for
proper and complete skeletal muscle regeneration. Anti-inflammatory macrophages promote myogenic differentiation and fusion (Saclier et al., 2013a; Saclier et al., 2013b; Varga et al., 2016b) , a finding of importance for skeletal muscle muscle regeneration where a sequential presence of prothen anti-inflammatory cells is necessary for efficient regeneration process (Arnold et al., 2007; Varga et al., 2013) . Therefore, the pro-resolving effect of ANXA1-AMPK signalling in macrophages is likely to be beneficial for skeletal muscle regeneration, as suggested by the positive effect of conditioned medium from ANXA1-treated macrophages on adult myogenesis in vitro.
In summary, we present here a novel mechanism governing the conversion of pro-inflammatory macrophages to a pro-resolving phenotype, linking leukocyte-derived ANXA1, FPR2/ALX and intracellular AMPK activation. This finding reinforces the position of the ANXA1-FPR2/ALX pathway as a pivotal regulator of inflammatory resolution, and suggests that it may represent a suitable target for therapeutic exploitation for the innovative treatment of pathologies characterised by chronic, non-resolving inflammation. 
Methods
Animals
All procedures were performed under the UK Animals (Scientific Procedures) Act, 1986 in the UK or in compliance with European legislation in France. Animal facilities are fully licensed by relevant national authorities and protocols have been validated by ethical committee. Male C57Bl/6 mice, male alx/fpr2/3 GFP/GFP mice (referred to as Fpr2/3 -/-) bearing a knocked-in green fluorescent protein (Dufton et al., 2010) and male anxA1 -/-mice (Hannon et al., 2003) , aged 10 weeks were used for in vivo experiments. Both transgenic strains were fully backcrossed onto a C57Bl/6 genetic background.
Production of Recombinant Human Annexin A1
Human recombinant annexin A1 (hrANXA1) was produced by a prokaryotic expression system and purified essentially as described previously (Kusters et al, 2015) . Briefly, cDNA for human ANXA1 was inserted into the expression vector pQE30Xa (Qiagen) and transfected into E.coli (#SG13009 pREP4, Novagen) which were then grown in Luria-Bertani broth medium supplemented with ampicillin (50 μg/ml, Roche), kanamycin (30 μg/ml, Thermofisher) and 0.5% glycerol. Protein overexpression was initiated by addition of 5mM isopropyl β-D-1-thiogalactopyranoside (Eurogentec) and proteins were purified by IMAC. Purity and homogeneity were assessed by SDS-PAGE, western blotting and MALDI-TOF/TOF analysis. Endotoxin was determined with the Endosafe-PTS (FDA-licensed LAL cartridge from Charles-River) according to the manufacturer's protocol. HrANXA1 contained < 0.2 unit endotoxin per mg hrANXA1 protein.
Skeletal Muscle Injury
Skeletal muscle injury was caused by intramuscular injection of cardiotoxin (Latoxan) in the Tibialis Anterior (TA) muscle of male animals, as described previously . Left TA muscles were injected with cardiotoxin (50 µl per TA, 12 µM); 1, 2, 7, 14 or 28 days post-lesioning animals were killed by exposure to CO 2 . TA were isolated and snap-frozen in liquid nitrogen-cooled isopentane for storage and later analysis.
Murine Bone Marrow-Derived Macrophages
Bone marrow-derived macrophages (BMDMs) were prepared from adult male wild-type sv129/C57Bl6 and Prkaa1 -/-mice (referred to as AMPKα1 -/- (Jorgensen et al., 2005) ). Mice were killed by cervical dislocation under isofluorane anaesthesia, and marrow was flushed from tibiae and femurs. Cells were plated, washed and grown for 6-7 days in DMEM High Glucose High Pyruvate, 20% heat inactivated fetal calf serum (ThermoFisher), 30% L929-cell conditioned medium, 1%
Amphotericin B (2.5 µg/ml, ThermoFisher) and 100 μg/ml streptomycin (ThermoFisher). For phenotypic characterisation, BMDMs were fixed for 10 minutes in 4% formaldehyde, permeabilized for 10 minutes in PBS with 0.5 % Triton X-100 and blocked for 1 hour in PBS with 4 % BSA. They were then labeled overnight at 4°C with anti-NOS2 (#ab15323, Abcam), anti-CCL3 (#ab32609, Abcam), anti-TGFβ1 (#ab64715, Abcam), anti-CD163 (#sc-20066, Santa-Cruz) and anti-CD206 (#sc-58987, Santa-Cruz), followed by incubation for 1 hour at 37°C with FITC-or Cy3-conjugated secondary antibodies (Jackson Immunoresearch Inc). Cells were stained with Hoechst (Sigma) and mounted in Fluoromount (Interchim) and pictures were taken on an Axio Imager.Z1 (Zeiss) at 20X of magnification connected to a CoolSNAP MYO CCD Camera (Photometrics).
In vitro model of adult myogenesis
Macrophages were obtained from bone marrow (BM) precursor cells that were cultured in DMEM containing 20% FBS and 30% conditioned medium of L929 cell line (enriched in CSF-1) for 7 days.
Macrophages were activated with human recombinant annexin A1 for 3 days (10 nM) in DMEM containing 10% FBS. After the washing steps, serum-free DMEM was added for 24 hr to obtain macrophage-conditioned medium. Murine myogenic precursor cells (MPCs) were obtained from TA muscle and cultured using standard conditions in DMEM/F12 medium (Gibco Life Technologies)
containing 20% heat inactivated Foetal Bovine Serum (FBS) and 2% G/Ultroser (Pall Inc). MPCs were seeded at 30,000 cell/cm 2 on Matrigel (diluted 1:10) and incubated for 3 days with conditioned medium containing 2% heat inactivated horse serum. Cells were then incubated with an anti-desmin antibody (#ab32362, Abcam), followed by a Cy3-conjugated secondary antibody (Jackson Immunoresearch Inc) Varga et al, 2016) . Cells were stained with Hoechst (Sigma) and mounted in Fluoromount (Interchim) and pictures were taken on Axio Observer.Z1
(Zeiss) at 20X of magnification connected to a CoolSNAP HQ2 CCD Camera (Photometrics
Bone Marrow Transplantation
Total bone marrow cells were isolated by flushing the tibiae and femurs of 8-to 20-week-old donor mice (wild-type or AnxA1 -/-males) with RPMI-1640 / 10% FBS. They were transplanted into 8-to 12-week-old recipient CX3CR1-GFP +/-males (monocytes/macrophages expressing GFP) previously lethally irradiated for 10 min with a dose of 0.85 Gy/min in an X-RAD 320 (Precision X-Ray). Total bone marrow cells were injected (10 7 cells diluted in 100 μL of RPMI-1640 / 50 % mouse serum) into the retro-orbital vein of recipient mice. After transplantation, mice were fed with ciprofloxacin (10 mg/kg/day) in the drinking water for 3-weeks. Engraftment efficiency was determined on peripheral blood 5 weeks after the transplantation and on bone marrow when mice were sacrificed by FACS 
Histological and Immunohistochemical Analysis
For histological analysis, muscles were harvested, snap frozen in liquid nitrogen-chilled isopentane and kept at -80°C until use. Cryosections (10µm) were prepared for hematoxylin-eosin ( 
In vivo Macrophage Phenotype Analysis
Macrophage phenotype was analyzed as previously described 
AMPKα1 siRNA
Primary human PBMC-derived macrophages were transfected with one of three different commercial siRNA sequences designed to target AMPKα1 or an Allstars negative control siRNA sequence using Hiperfect transfection reagent according to the manufacturer's instructions (final concentration 2 nM; all Qiagen GmbH, Hilden, Germany), alongside mock transfected cells. After 48 hours, cells were analysed for phenotypic conversion following hrANXA1 treatment (6 hours, 10 nM). A proportion of cells were analysed for AMPKα1 expression by western blot using a rabbit polyclonal antibody raised against human the AMPKα1 subunit (1:1,000, #2795, Cell Signalling Technology) and for β-actin expression using a mouse monoclonal antibody (1:10,000; #A5316, Sigma).
Human Macrophage Flow Cytometry Analysis
Primary human PBMC-derived macrophages were labelled with FITC-conjugated mouse monoclonal anti-MHCII (#11-9956-42, Thermofisher) and APC-conjugated mouse monoclonal anti-CD206 (#17-2069-42, Thermofisher) or isotype controls (all Thermofisher) according to manufacturer's protocols.
In all cases, 20,000 events were acquired using a FACSCalibur flow cytometer (Becton Dickinson), and analysed using FlowJo analysis software (Version 9.2, Treestar Inc). In some cases, macrophages were analysed for surface expression of FPR2/ALX; surface FcγR were blocked by incubation for 20 minutes at 4°C with IgG block (ThermoFisher Scientific, UK), followed by incubation for 30 minutes at 4°C with mouse monoclonal anti-FPR2/ALX (1µg/106 cells; GM1D6, Aldevron, Freiburg, Germany) then incubation for 30 minutes at 4°C with secondary antibody (AF488-conjugated goat anti-mouse 1:300; ThermoFisher Scientific, UK).
Western Blot Analysis
Samples boiled in 6× Laemmli buffer were subjected to standard SDS-PAGE (10%) and electrophoretically blotted onto Immobilon-P polyvinylidene difluoride membranes (Millipore, Watford, UK). Membranes were incubated with antibodies raised against human phospho- at 10 minute intervals; membranes were then incubated with secondary antibody (horseradish peroxidase-conjugated goat anti-mouse 1:5000; ThermoFisher), for 2 hours at room temperature.
Proteins were then detected using the enhanced chemiluminescence detection kit and visualized on Hyperfilm (Amersham Biosciences). Films were digitised and analysed using ImageJ 1.51w software (National Institutes of Health).
Quantitative RT-PCR
Total RNA was prepared from primary human PBMC-derived macrophages using TRIzol reagent (Life 
Statistical Analysis
All quantified in vitro data are derived from at least three independent donors, with experiments performed in triplicate, and are expressed as mean ± SEM. Murine in vivo experiments were performed with a group size of n=6, sufficient to identify a 20% effect size with a power of 0.8, and are expressed as mean ± SEM. Data were analyzed by one-or two-way ANOVA as appropriate, with post hoc comparison using Tukey's HSD test. For murine in vitro experiments, at least 3 independent experiments were performed and statistical significance was determined using Student's t test. In all cases, a P<0.05 was taken as indicating statistical significance. 
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